Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma

Prakash Ambady; Rongwei Fu; Laszlo Szidonya; David M. Peereboom; Nancy D. Doolittle; Edward A. Neuwelt

doi:10.1007/s11060-020-03411-0

Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma

Prakash Ambady, Rongwei Fu, Laszlo Szidonya, David M. Peereboom, Nancy D. Doolittle, Edward A. Neuwelt

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Purpose: The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. Methods: We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). Results: Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08–0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26–1.43, P = 0.259). Conclusion: We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.

Original language	English (US)
Pages (from-to)	171-176
Number of pages	6
Journal	Journal of Neuro-Oncology
Volume	147
Issue number	1
DOIs	https://doi.org/10.1007/s11060-020-03411-0
State	Published - Mar 1 2020

Keywords

High-dose methotrexate
Maintenance therapy
Primary CNS lymphoma
Rituximab

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/s11060-020-03411-0

Cite this

@article{483ca5d2836b4ea79cd843765406e699,

title = "Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma",

abstract = "Purpose: The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. Methods: We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). Results: Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08–0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26–1.43, P = 0.259). Conclusion: We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.",

keywords = "High-dose methotrexate, Maintenance therapy, Primary CNS lymphoma, Rituximab",

author = "Prakash Ambady and Rongwei Fu and Laszlo Szidonya and Peereboom, {David M.} and Doolittle, {Nancy D.} and Neuwelt, {Edward A.}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2020",

month = mar,

day = "1",

doi = "10.1007/s11060-020-03411-0",

language = "English (US)",

volume = "147",

pages = "171--176",

journal = "Journal of Neuro-Oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma

AU - Ambady, Prakash

AU - Fu, Rongwei

AU - Szidonya, Laszlo

AU - Peereboom, David M.

AU - Doolittle, Nancy D.

AU - Neuwelt, Edward A.

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Purpose: The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. Methods: We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). Results: Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08–0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26–1.43, P = 0.259). Conclusion: We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.

AB - Purpose: The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. Methods: We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). Results: Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08–0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26–1.43, P = 0.259). Conclusion: We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.

KW - High-dose methotrexate

KW - Maintenance therapy

KW - Primary CNS lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85079494142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079494142&partnerID=8YFLogxK

U2 - 10.1007/s11060-020-03411-0

DO - 10.1007/s11060-020-03411-0

M3 - Article

C2 - 32026432

AN - SCOPUS:85079494142

SN - 0167-594X

VL - 147

SP - 171

EP - 176

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

IS - 1

ER -

Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this